News coverage about Presbia PLC (NASDAQ:LENS) has been trending positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Presbia PLC earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 44.5933450704575 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
A number of equities analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Presbia PLC in a research note on Tuesday, May 23rd. Rodman & Renshaw decreased their target price on Presbia PLC from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Monday, May 22nd. Zacks Investment Research upgraded Presbia PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, July 25th. Finally, ValuEngine upgraded Presbia PLC from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Presbia PLC currently has an average rating of “Hold” and a consensus price target of $12.00.
Shares of Presbia PLC (NASDAQ:LENS) traded up 4.10% during trading on Tuesday, reaching $3.30. The company’s stock had a trading volume of 17,169 shares. The stock’s market capitalization is $55.95 million. Presbia PLC has a 1-year low of $2.71 and a 1-year high of $4.97. The company’s 50-day moving average price is $2.93 and its 200 day moving average price is $2.96.
About Presbia PLC
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States.
Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with MarketBeat.com's FREE daily email newsletter.